Further information
STFC’s Deep Tech Catalyst encompasses:
- Space (European Space Agency BIC UK), Harwell Campus, Oxfordshire
- Biotechnology (Bio BIC), Sci-Tech Daresbury, Liverpool City Region
- Quantum Computing BIC (QuBIC) with the National Quantum Computing Centre, Harwell Campus, Oxfordshire
- Health BIC, Sci-Tech Daresbury, Liverpool City Region
- Higgs Centre for Innovation, Royal Observatory, Edinburgh
Meet the businesses joining the Health BIC
EPONA Bio
Epona Bio is developing a new class of therapies designed to advance the treatment of eye diseases.
Lynch Enterprises Ltd
Helfy combines doctor-led diagnostics, personalised lifestyle prescriptions, and education into one platform.
The platform offers real-time, doctor-reviewed blood testing with personalised insights to help people prevent burnout, boost performance, and live longer.
They combine advanced diagnostics, behavioural science, and lifestyle medicine in a digital experience, backed by UK-registered doctors.
The plan is to tap into underused corporate health budgets, sell directly to employers, brokers, and high-performance individuals, with recurring revenue from diagnostics, subscriptions, and clinical services.
OCUWELL
OCUWELL is developing portable imaging devices and software that enable accurate, repeatable corneal topography at a fraction of the cost and size of traditional machines.
Its integrated solution combines high-precision hardware with intelligent analysis software, empowering earlier intervention, remote care, and improved patient outcomes.
Averywell
Averywell is a med-tech company focused on the early detection and management of lung cancer through its proprietary liquid biopsy test, mirLung Dx.
The test analyses microRNA biomarkers that can indicate the presence of lung cancer even before symptoms appear, enabling earlier diagnosis and improved clinical decision-making.
Caremixer
Caremixer is developing a real-time digital communication platform, Carebell, that connects professionals, teams and patients across the NHS and wider health and care system, reducing the impact of fragmented care.
It improves coordination and continuity, supporting the delivery of joined-up, personalised, patient care.
Caremixer is a clinically founded organisation established to bring data and AI driven innovation to health and social care.
Respiosa Health
Respiosa is transforming second-line treatment for obstructive sleep apnea with a smart oral implant that passively prevents tongue collapse.
This is a leading cause of airway obstruction in Continuous Positive Airway Pressure -intolerant patients.
Implanted in a 30-minute ear, nose, and throat procedure, Respiosa offers durable, adjustable, and invisible therapy that requires no user effort.
It delivers effective therapy without masks, wires, or nightly routines, bridging the critical care gap for millions.
PB Biologics
PB Biologics are solving the limitations of traditional and thermally inactivated probiotics by developing a patented Programmed Cell Death method that inactivates bacteria without destroying their structure.
This approach creates precision biological functionality while eliminating the risk of horizontal gene transfer.
The result is safer, more cost-effective, and scalable microbiome therapies and consumer products.
Sarvas Health
Sarvas is a health tech company focused on predicting the risk of onset of chronic disease using an AI foundation model and primary care electronic health records.
Their launch product, SarvasHF, identifies patients at risk of developing heart failure within a five-year window, enabling earlier testing and intervention in primary care, where symptoms often first appear, but are currently underdiagnosed.
SIMFONIK
SIMFONIK is a mobile-based audio-led simulation platform redefining how empathy and compassionate communication are taught.
Delivered through bone-conduction headphones, it blends authentic patient voice recordings, immersive storytelling and interactive roleplay to create emotionally resonant learning experiences, without costly simulation suites or virtual reality setups.
Participants engage in paired scenarios, each guided by a unique audio perspective within a shared narrative, mirroring real patient experiences.
Every simulation concludes with structured peer and group reflections, embedding emotional insight into practice and transforming empathy from an abstract concept into an embodied skill.
Cardiology Devices
MyoCaid by Cardiology Devices Ltd is a breakthrough support device designed for patients with advanced heart failure who are unsuitable for conventional Left Ventricular Assist Devices or transplantation.
With easier implantation, fewer complications and a novel mechanism, enabling transcutaneous charging and reduced stroke risk, MyoCaid addresses a critical unmet need in a growing UK market of 20,000 patients annually.
Expected to extend life by six years and deliver £76,000 in health economic benefits per case, MyoCaid is set to disrupt a £50 billion global heart failure market.
